76,900 Shares in Hemab Therapeutics Holdings, Inc. $COAG Bought by State Street Corp

Key Points

• State Street Corp acquired 76,900 shares of Hemab Therapeutics in the second quarter, worth approximately $2.83 million and representing about 0.16% of the company. Several other institutional investors, including Citadel Advisors and Braidwell, also initiated positions.
• Hemab shares opened at $34.74, with a 52-week range of $23.00 to $55.42 and a market capitalization of roughly $1.62 billion. The company reported a quarterly loss of $0.80 per share, missing analysts’ $0.63-loss estimate.
• Analyst sentiment remains generally positive, with five Buy, one Hold, and one Sell rating, producing a “Moderate Buy” consensus and an average price target of $51.40. Hemab is developing treatments for serious bleeding disorders, led by its HMB-001 program for Glanzmann thrombasthenia.

State Street Corp bought a new stake in Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 76,900 shares of the company's stock, valued at approximately $2,825,000. State Street Corp owned approximately 0.16% of Hemab Therapeutics as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Squarepoint Ops LLC acquired a new position in Hemab Therapeutics during the 2nd quarter worth approximately $230,000. The Manufacturers Life Insurance Company bought a new stake in Hemab Therapeutics during the 2nd quarter worth approximately $688,000. Opaleye Management Inc. bought a new position in shares of Hemab Therapeutics during the second quarter valued at $1,750,000. Braidwell LP acquired a new position in shares of Hemab Therapeutics during the second quarter worth $5,877,000. Finally, Citadel Advisors LLC acquired a new position in shares of Hemab Therapeutics during the second quarter worth $19,226,000.

Hemab Therapeutics Stock Performance

Shares of Hemab Therapeutics stock opened at $34.74 on Friday. The stock's 50-day simple moving average is $46.06. Hemab Therapeutics Holdings, Inc. has a 1-year low of $23.00 and a 1-year high of $55.42. The firm has a market cap of $1.62 billion and a P/E ratio of -1.40.

Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.17). Analysts forecast that Hemab Therapeutics Holdings, Inc. will post -3.09 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

COAG has been the subject of a number of recent research reports. Jefferies Financial Group increased their price objective on Hemab Therapeutics from $39.00 to $47.00 and gave the company a "buy" rating in a report on Monday, July 13th. Weiss Ratings assumed coverage on Hemab Therapeutics in a research report on Thursday, August 13th. They issued a "sell (d+)" rating on the stock. HC Wainwright increased their price target on Hemab Therapeutics from $52.00 to $60.00 and gave the company a "buy" rating in a research note on Tuesday, August 11th. Finally, Wedbush raised their price objective on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an "outperform" rating in a research report on Wednesday, August 12th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $51.40.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing treatments for serious and underserved bleeding disorders. The company aims to create therapies that address limitations of existing approaches, including the need for frequent administration and the challenges associated with complex blood-product-based treatments.

Its lead investigational program, HMB-001, is being developed for Glanzmann thrombasthenia, a rare inherited disorder in which platelets do not function properly and can cause severe bleeding.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.